PubMed Health⌕ Search

Biomedical subjects

J Halper

Publications and source records attributed to J Halper.

48 records · Page 3Linked to original sources

Contrasting patterns of newer histocompatibility determinants in patients with rheumatoid arthritis and systemic lupus erythematosus.

The Ia alloantigens as measures of different alleles of loci in the major histocompatibility complex were determined in patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). The Ia specificities of reagents used were defined by their pattern of reaction with lymphoblastoid lines derived from normal donors homozygous for HLA-D determinants. The reagent specificities included those associated with a single Dw type as well as those reacting with a single specificity shared by several Dw types. Patients with RA had a marked elevation in the frequency of alloantigens detected by reagent sera that recognize various determinants shared by cell lines from HLA-Dw4, Dw7, or Dw10 individuals (Ia 4-7-10). The frequency of mixed lymphocyte culture alleles Dw4 and Dw10 was found to be increased; however this elevation did not approach the higher frequency for the serologically determined antigens of the Ia 4-7-10 group. In contrast, patients with SLE had an increased frequency of reactions with the reagent alloantisera defined by reactions with either HLA-Dw2 or Dw3 positive cell lines. The data suggest that immunogenetic factors are relevant to both groups of patients, but that these are entirely distinct for each disease.

Arthritis, Rheumatoid↗

Patterns of expression of human "Ia-like" antigens during the terminal stages of B cell development.

The "Ia-like" antigens characteristically present on the membrane of B lymphocytes were shown to be absent in most terminally differentiated Ig-producing plasma cells. This was most evident in analyses of myeloma plasma cells that uniformly lacked the Ia-antigens. Also, in B lymphoid cell lines, the lymphoblasts were uniformly Ia-positive but the plasma cells were negative. In contrast, however, the majority of plasma cells produced after pokeweed mitogen stimulation remained positive. Plasma cells in tonsil and in the tissue of peripheral blood of patients with Wladenström's macroglobulinemia were also sometimes Ia-positive although the majority were negative. Studies of membrane IgM and IgD indicated a similar loss in some instances. However, the SIg and Ia antigens were not invariably associated. These results lead to the conclusion that Ia-antigens are differentiation antigens for B cells and are usually lost by the end stage cells in this series.

B-Lymphocytes↗

Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation.

Human B lymphocyte antigens analogous to the murine Ia determinants were found on myeloblasts and promyelocytes but not on more mature granulocytes. This was apparent by fluorescent staining with both human alloantisera and rabbit antisera to the isolated Ia-like proteins. The cells of patients with chronic myelocytic leukemia showed this difference especially clearly. Separation of the myeloblasts and promyelocytes by multistep density gradient fractionation produced a marked enrichment of the positive cells. The remaining cells from higher density fractions were more-mature neutrophils that were essentially negative. In acute myeloid leukemia, in which myeloid cells early in differentiation predominate, the vast majority of cells were strongly positive. Similar results were obtained with normal bone marrow cells. Here also, only the early forms of the myeloid series separated by gradient centrifugation had Ia antigens. Evidence was also obtained for the presence of Ia determinants on cells with the appearance of early erythroid precursors. Support for the presence of the Ia determinants on granulocyte-macrophage committed stem cells was provided by the inhibition of granulocyte colony formation in agar cultures following preincubation of normal bone marrow with antiserum and complement. Cross absorptions with purified preparations of immature cells provided evidence for the close similarity of the antigenic determinants on both myeloblasts and B cells. A 28,000-37,000-dalton bimolecular complex obtained from myeloblast membranes contained the Ia determinants and was similar to that obtained from peripheral blood B cell membranes.

B-Lymphocytes↗

Studies with B-cell allo- and hetero-antisera: parallel reactivity and special properties.

The expression of B-cell antigens on various cell populations was studied through the use of human alloantisera and with heteroantisera raised to preparations of the alloantigen bearing molecules isolated from B-cell lines. The allo-and hetero-antisera competed with each other in blocking experiments and gave closely parallel results, reacting with normal and leukemic B lymphocytes, monocytes, E-rosette-negative acute lymphatic leukemias, all acute and certain chronic myelogenous leukemias, and a minor population of cells in fetal spleen and liver. These highly immunogenic surface components appeared to comprise the dominant B- cell specific plasma membrane determinants. Neither type of antiserum reacted with any but a minor population of normal or pokeweed-mitogen-transformed T cells, fetal thymic lymphocytes, E-rosette-positive acute lymphatic leukemias, or Sezary-cell leukemia. Through the use of these antisera evidence was obtained that Fc-receptor-bearing Ig-negative lymphocytes were divisible into two groups according to the presence or absence of the B-cell antigens. Both hetero- and allo-antisera blocked binding of immune complexes or antibody-coated ox erythrocytes to Fc receptors on B cells. F(ab')2 fragments of the heteroantibodies strongly inhibited antibody-dependent cell-mediated killing.

Animals↗

The functional model in multiple sclerosis.

Multiple sclerosis (MS) is a sometimes progressive neurologic disorder of young adults that can result in disability and markedly altered lifestyles. Traditionally, MS has had a negative impact on both the patient and healthcare provider, because there is no known cure and treatments are symptomatic. The Functional Model offers a new way of focusing on MS by evaluating function rather than dysfunction, and by emphasizing healthcare and self-care activities that may help the patient move from dependency to a more independent functional status. This model provides rehabilitation personnel with a tool to design individualized interventions and encourage the patient to focus on strengths rather than weaknesses.

Activities of Daily Living↗

Adherence to disease-modifying therapy in multiple sclerosis: Part I.

Multiple sclerosis (MS) is a chronic, debilitating disease for which there is no cure. However, the recent introduction of injectable immunomodulating agents has made it possible to reduce the frequency of relapsing episodes and to possibly slow its progression. The use of these agents is recommended by the National MS Society, however, their true potential cannot be realized if patients do not accept them and healthcare professionals do not promote them. Because MS is unpredictable, and treatments can produce side effects, ensuring adherence to the recommended therapy is a complex and challenging issue. A better understanding of the obstacles to adherence, and the identification of possible solutions, should be of value to nurses, who have numerous opportunities to encourage patients to initiate and continue therapy. This article, which is in two parts, describes the particular problems of treatment adherence, and proposes that the transtheoretical model of behavior change can be useful in achieving treatment goals in MS and in other chronic disease states. This model is based upon the concept that a patient's "readiness for change" is crucial, and that attempts at intervention should be sensitive to the patient's changing conditions and state of mind. Nurses who work with patients with MS and other chronic diseases can apply the model to help their patients accept and adhere to the demands of ongoing treatment.

Chronic Disease↗

Adherence to disease-modifying therapy in multiple sclerosis: Part II.

Multiple sclerosis (MS) is a chronic, debilitating disease for which there is no cure; however, the recent introduction of injectable immunomodulating agents has reduced the rate of relapsing episodes and possibly slowed the progression of the disease. These disease-modifying agents are recommended by the National MS Society, but their true potential cannot be realized if patients do not accept them and healthcare professionals do not promote them. Since MS has an unpredictable course, and treatments can produce side effects, adherence to the recommended therapy is a complex and challenging issue. Improved understanding of the obstacles to adherence and the identification of possible solutions should be of value to nurses, who have numerous opportunities to encourage patients to initiate and continue therapy. Part I of this article, published in the September/October 2001 issue of Rehabilitation Nursing, described the particular problems of treatment adherence in MS. Part II proposes that the transtheoretical model of behavior change can be a useful tool in achieving both patient acceptance and treatment goals. This model is founded upon the concept that readiness for change is crucial, and that attempts at intervention should be sensitive to the patients' changing conditions and states of mind.

Humans↗

Transforming growth factor type e is a novel mediator of wound repair.

Transforming growth factor type e is a potent mitogen for epithelial and fibroblastic cells in vitro. It is primarily produced by epithelial tissues and cells, including normal skin keratinocytes. In this study we examined the effects of transforming growth factor type e in vivo and in vitro. On application of transforming growth factor type e to the chorioallantoic membrane of 8-day-old chick embryos, we noted a prominent thickening of the membrane caused primarily by fibroblastic and epithelial proliferation. In a subsequent study, transforming growth factor type e suspended in Matrigel was injected subcutaneously into the abdominal wall of Swiss National Institutes of Health mice. Significant influx of first neutrophils and then macrophages into the gel of transforming growth factor type e-treated mice, but not of control mice, was observed. Transforming growth factor type e also exhibited a potent chemoattractive effect on the J774 macrophage cell line in vitro. In transcutaneous mouse wounds, topical administration of transforming growth factor type e led first to an influx of neutrophils and macrophages, followed by an increased formation of granulation tissue in the transforming growth factor type e-treated wounds. These results suggest that transforming growth factor type e plays an important role in wound healing as a chemoattractant for neutrophils and macrophages and as a mitogen for epithelial and fibroblastic cells.

Journal Article↗